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Background: Currently, lung transplantation (LTX) is considered to be a curative treatment option 
in patients with end-stage lung disease. Although pulmonary hypertension (PH), confirmed by cardiac 
catheterization, is a prognostic factor in patients undergoing LTX, the prognostic value of PH in Asian lung 
transplant recipients remains uncertain. In this study, we aimed to determine whether PH before LTX may 
serve as a prognostic factor for survival in Asian patients. 
Methods: The medical records of 50 patients [male, 27; female, 23; mean age, 51.0 (41.0–60.0) years], who 
received preoperative right heart catheterization (RHC) and echocardiography before single or double LTX 
at Severance Hospital between January 2010 and December 2014, were reviewed. The relationship between 
1-year survival after LTX and PH [mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest] was 
evaluated. 
Results: The mean right ventricular systolic pressure and mPAP were 48.5 (22.8) and 30.0 (24.0–40.0) mmHg. 
Of the 50 patients, 17 (34.0%) died within a year after LTX. The 1-year survival rate among patients with 
mPAP ≥25 mmHg (58.8%) was lower than the survival rate among patients with mPAP <25 mmHg (87.5%). 
Pre-transplantation mPAP of ≥25 mmHg was associated with post-transplantation survival [hazard ratio (HR), 
4.832; 95% confidence interval (CI), 1.080–21.608, P=0.039]. The presence of preoperative PH was also 
associated with an increased risk of postoperative complications. 
Conclusions: Confirmation of PH via preoperative cardiac catheterization was associated with the 
prognosis of the patient after LTX. Clinicians should consider the necessity for early transplantation surgery 
before the mPAP reaches ≥25 mmHg. 
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Introduction 
Management approaches for various intractable lung 
diseases have been transformed with the advancement of 
lung transplantation (LTX), which is one of the treatment 
options utilized at the endpoint of several lung diseases. 
Transplantation of other solid organs has produced better 
results and undergone greater improvement than LTX; 
thus, the outcomes of LTX remain among the worst overall 
for organ transplantation (1,2). However, the frequency and 
success rate of LTX have improved in recent years, with 
the increased success attributable to advances in post-LTX 
immunosuppression treatment (2,3); nevertheless, progress 
in LTX outcomes remains a challenging area of medicine. 
The survival rate associated with LTX has been increasing, 
such that the majority of deaths after LTX occur within the 
first year (4). Therefore, the identification of prognostic 
factors of 1-year mortality in lung transplant recipients 
might facilitate improvement of long term clinical outcomes 
after LTX. 
There is a growing body of evidence that pulmonary 
hypertension (PH) associated with lung disease is a 
predictor of disease severity and mortality in patients 
awaiting LTX (5-7). Patients with PH suffer hypoxia, 
hypercapnia and respiratory acidosis, as a result of 
increased peripheral vascular resistance and right heart 
failure (8,9); these conditions can eventually lead to 
death. Previous studies have reported that PH, when 
confirmed by cardiac catheterization, is an independent 
predictive factor for survival after LTX (7,10-13). In 
addition, several studies have also analyzed post-LTX 
prognosis via echocardiography (14-16). However, 
almost all studies were exclusively designed for idiopathic 
pulmonary fibrosis (IPF) or other individual lung 
diseases. Moreover, there is a lack of consensus regarding 
predictive factors between IPF patients and patients who 
have other lung pathologies (17).
Despite the increasing popularity of LTX, there 
continue to be limited reports on the prognostic value 
of PH in lung transplant recipients. In addition, because 
of the small number of recipients of LTX in Asia, there 
are no reports in an Asian population regarding the 
clinical significance of PH in post-LTX survival. To 
determine the impact of PH on post-LTX survival, this 
study analyzed the characteristics and prognoses of lung 
transplant recipients with or without preoperative PH via 
echocardiography and right heart catheterization (RHC) 
in a Korean population.
Methods 
Study design and population
We reviewed the medical records of 83 patients who 
underwent single or double LTX between January 2010 
and July 2014 at Severance Hospital, Yonsei University, 
Republic of Korea. We excluded patients who did not 
undergo preoperative echocardiography or cardiac 
catheterization within 1 year prior to LTX, as well as those 
who missed follow-up echocardiography within 3 months 
after LTX. Thus, of the 83 patients whose records were 
initially reviewed, 50 were included in the study. From 
the database, we extracted all variables related to patient 
demographic characteristics and pre- and postoperative 
outcomes, in order to evaluate the relationship between 
PH and 1-year survival after LTX. Patient survival status 
was determined on the basis of hospital records. Donor 
data were collected from the Korean Network of Organ 
Sharing (KONOS) database. Additional variables included 
demographic characteristics, ischemic time, and donor-
recipient size mismatch. All donated lungs from declared 
brain-dead patients were preserved in low-potassium 
dextran solution (Perfadex; Duraent Biologicals, Hyderabad, 
India). We divided the study subjects into two groups, 
according to their PH status. 
RHC and echocardiography
RHC was performed at rest using a Swan-Ganz catheter. 
PH was defined as an increase in resting mean pulmonary 
arterial pressure (mPAP) of ≥25 mmHg, as assessed 
by RHC, using European Society of Cardiology and 
European Respiratory Society guidelines (18). Other 
echocardiographic variables were collected, such as ejection 
fraction (EF); right arterial pressure (RAP); regional 
wall motion abnormality (RWMA); ratio of mitral peak 
velocity of early filling (E) to early diastolic mitral annular 
velocity (E'), i.e., E/E'; and RV systolic pressure (RVSP). 
The characteristics of echocardiography were compared 
with RHC data, and correlation analysis was performed to 
investigate correlations with PH.
Statistical analysis
All data were analyzed using SPSS version 23 (IBM, 
Armonk,  NY, USA).  Data are expressed as  mean 
values with standard deviations or median values with 
interquartile ranges (IQRs), as appropriate. Continuous 
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variables were compared by Student’s t-test; categorical 
variables were compared by either the Chi-squared test or 
Fisher’s exact test, as appropriate. Comparison of survival 
between patients with and without preoperative PH was 
performed by the log-rank test. The relationship between 
RHC and echocardiography-derived hemodynamics was 
assessed using the Pearson correlation. One-year survival 
following LTX was analyzed by Kaplan-Meier analysis; this 
measurement was compared between recipients with and 
without preoperative PH. Association of echocardiographic 
and hemodynamic parameters with clinical outcomes was 
evaluated by Cox proportional hazards regression analysis. 
Hazard ratios (HRs) and 95% confidence intervals (CIs) 
were calculated. In all statistical analyses, a two-tailed 
P value of <0.05 was considered to be statistically significant.
Ethical approval
The study protocol was approved by the institutional review 
board of Severance Hospital (approval No. 2013-0522-019). 
In addition, this study was conducted in compliance with 
the principles set in the 2000 Declaration of Helsinki, as 
well as the 2008 Declaration of Istanbul.
Results
Baseline characteristics of lung transplant recipients
Table 1 describes the baseline characteristics of all patients 
who were included in this analysis, comprising 50 [27 
males (54%) and 23 females (46%)] patients. The mean 
age of the patients was 51.0 (41.0–60.0) years; 47 (94.0%) 
patients underwent double LTX. On the basis of mPAP 
values, 34 patients (68.0%) were classified into the PH 
group; the remaining patients comprised the non-PH 
group. Comparison of demographic, hemodynamic, and 
pulmonary function characteristics among lung transplant 
recipients was performed, according to PH status. The 
distribution of underlying lung diseases was as follows: IPF, 
22 patients (44.0%); lymphangioleiomyomatosis, 8 patients 
(16.0%); connective tissue disease, 6 patients (12.0%); 
bronchiectasis, 5 patients (10.0%); bronchiolitis obliterans 
after stem cell transplantation, 4 patients (8.0%); diffuse 
panbronchiolitis, 2 patients (4.0%); and others [chronic 
obstructive pulmonary disease, other pulmonary fibrosis, 
and pulmonary Langerhans cell histiocytosis, 1 patient each 
(2.0%)]. There was no statistically significant difference 
in the distribution of the underlying diseases. Pulmonary 
function tests were administered before LTX; lung 
transplant recipients exhibited underlying lung diseases with 
severe restrictive patterns, as evidenced by the relatively low 
mean values of functional vital capacity (45.6%±16.3%) and 
diffusing capacity of the lung for carbon monoxide (DLCO; 
37.8%±18.8%). The mean values of preoperative RVSP 
and mPAP (determined by echocardiography and RHC, 
respectively) were 48.5±22.8 and 30.0 (24.0–40.0) mmHg, 
respectively. Comparison of baseline characteristics revealed 
that there were significant differences between the two 
groups regarding most hemodynamic variables, suggesting 
that hemodynamic variables may act as a prognostic factor; 
however, the only significant prognostic factors in both 
univariate analysis and multivariate analysis were mPAP 
and RAP. 
Clinical predictors of 1-year survival after LTX
Of the 50 patients in the study, 17 (34.0%) died within 
1 year after LTX. The 1-year survival rate of lung transplant 
recipients was higher in the PH group; the survival rates 
of patients with and without PH were 58.8% and 87.0%, 
respectively (log-rank test, P=0.030; Figure 1). Table 2 
presents the results of univariate analysis of predictive values 
for 1-year survival after LTX. Old age, male sex, higher 
BMI, RAP, and mPAP were identified as independent 
prognostic factors. 
The results of multivariate Cox proportional hazards 
analysis of age, sex, BMI, underlying disease (IPF vs. non-
IPF), and mPAP—all of which were identified as significant 
prognostic factors in univariate analysis—revealed an HR 
of 4.832 (95% CI, 1.080–21.608; P=0.039) for survival in 
patients with mPAP ≥25 mmHg. These results strongly 
suggest that preoperative PH significantly affects the 
chances of 1-year survival (Table 3). 
Postoperative complications among lung transplant 
recipients
Table 4  presents the comparison of postoperative 
complications, occurring within 3 months of LTX, in lung 
transplant recipients. Complications such as sepsis, acute 
kidney injury, acute rejection, postoperative bleeding, and 
grade 3 primary graft dysfunction were more frequent in 
the PH group than in the non-PH group. The proportion 
of complications was higher in the PH group than in the 
non-PH group. 
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Table 1 Comparison of baseline characteristics of patients with and without pulmonary hypertension before lung transplantation (N=50)
Variables Patient without PH (n=16) Patients with PH (n=34) Total (n=50) P value
Age, years 51.5 (39.5–58.0) 51.0 (43.0–60.0) 51.0 (41.0–60.0) 0.755
Male gender, n (%) 7 (43.8) 20 (58.8) 27 (54.0) 0.488
Body mass index, kg/m2 18.6 (3.7) 20.6 (4.0) 19.9 (4.0) 0.097
Smoking, pack years 22.0 (20.0–26.0) 40.0 (16.0–53.0) 22.0 (18.5–45.0) 0.420
Underlying diseases, n (%) 0.133
IPF, n (%) 10 (62.5) 12 (35.3) 22 (44.0)
Non-IPF, n (%)* 6 (37.5)† 22 (64.7)‡ 28 (56.0)
Double LTX, n (%) 16 (100.0) 31 (91.2) 47 (94.0) 0.557
Cr, mg/dL 0.6 (0.2) 0.6 (0.2) 0.6 (0.2) 0.951
Albumin, mg/dL 3.6 (2.9–4.2) 3.8 (3.0–4.2) 3.8 (3.0–4.2) 0.884
NT-ProBNP, pg/mL 62.0 (23.0–167.5) 49.0 (23.5–895.0) 51.0 (23.0–714.0) 0.623
Coronary disease, n (%) 2 (12.5) 8 (23.5) 10 (20.0) 0.681
DM, n (%) 3 (18.8) 6 (17.6) 9 (18.0) 1.000
6MWT, M 290.0 (170.0–317.5) 204.1 (125.9) 222.7 (128.3) 0.151
FEV1, % predicted 44.6 (17.6) 40.7 (20.4) 41.9 (19.4) 0.509
FVC, % predicted 43.2 (15.5) 46.8 (16.8) 45.6 (16.3) 0.483
DLCO, mL/mmHg/min 45.73 (20.9) 33.72 (16.5) 37.8 (18.8) 0.299
Pre-op MV, n (%) 2 (12.5) 5 (14.7) 7 (14.0) 1.000
Pre-op OP ECMO, n (%) 0 ( 0.0) 2 ( 5.9) 2 (4.0) 0.829
Echocardiography data
EF, % 65.1(8.0) 63.7 (9.3) 64.1 (8.9) 0.618
RWMA, n (%) 1 (6.3) 2 (5.9) 3 ( 6.0) 1.000
RAP, mmHg 5.0 (1.3) 8.0 (4.9) 7.2 (4.3) 0.056
RVSP, mmHg 39.8 (14.1) 52.2 (24.9) 48.5 (22.8) 0.037
E/E' ratio 8.8 (2.0) 9.4 (2.8) 9.2 (2.5) 0.461
Hemodynamic data
mPAP, mmHg 21.1 (19.0–23.5) 32.5 (28.0–40.6) 30.0 (24.0–40.0) <0.001
RAP, mmHg 6.0 (3.5–8.5) 10.0 (6.0–15.0) 8.0 (5.0–13.0) 0.008
RVP, mmHg 29.5 (27.0–36.5) 43.0 (32.0–57.0) 36.5 (27.0–52.0) 0.010
PCWP, mmHg 11.0 (8.5–12.0) 12.0 (10.0–21.0) 11.0 (9.5–20.5) 0.052
CO, L/min 4.5 (1.3) 5.1 (1.1) 4.7 (1.2) 0.042
CI, L/min/m2 2.8 (0.8) 3.4 (0.8) 3.0 (0.9) 0.092
Table 1 (continued)
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Discussion
This study investigated the association between 1-year 
mortality and preoperative PH among patients who 
underwent LTX, revealing higher rates of 1-year mortality 
and postoperative complications among patients with 
preoperative PH, relative to patients without preoperative 
PH. Thus, the presence of preoperative PH was associated 
with an increased risk of postoperative complications and 
mortality.
The presence of PH is a significant prognostic factor in 
patients with end-stage lung diseases. Among patients with 
COPD, up to 90% of those with stage IV disease (according 
to the Global Initiative for Chronic Obstructive Lung Disease 
guidelines) demonstrate mPAP of >20 mmHg (8). In addition, 
the prevalence of PH among patients with IPF ranges from 
31.6% to 84% (10,13,19). Similarly, in various lung diseases, 
most patients develop PH with disease progression (17). It is 
interesting to note that, among lung transplant recipients in 
the present study, preoperative PH was associated with poor 
Table 1 (continued)
Variables Patient without PH (n=16) Patients with PH (n=34) Total (n=50) P value
Donor
Age, years 44.0 (34.5–51.0) 41.0 (37.0–47.0) 42.0 (37.0–50.0) 0.487
Male gender, n (%) 8 (50.0) 25 (73.5) 33 (66.0) 0.139
Body mass index, kg/m2 22.4 (2.9) 22.4 (3.0) 22.4 (2.9) 0.982
Smoking, pack years 9.1 (2.5–13.8) 8.8 (3.2–15.0) 10.0 (2.5–15.0) 0.799
Ischemic time, min 219.5 (160.0–265.5) 215.0 (181.5–251.0) 216.0 (176.0–254.5) 0.875
Size mismatch, n (%) 4 (25.0) 7 (20.6) 11 (22.0) 1.000
Values are expressed as mean (SD) or median (IQR). *, the distribution of underlying lung diseases; †, bronchiolitis obliterans after stem 
cell transplantation, 4 (25.0%); lymphangioleiomyomatosis, 1 (6.3%); connective tissue disease, 1 (6.3%); ‡, lymphangioleiomyomatosis, 7 
(20.6%); bronchiectasis, 5 (14.7%); connective tissue disease, 5 (14.7%); diffuse panbronchiolitis, 2 (5.9%); chronic obstructive pulmonary 
disease, 1 (2.9%); pulmonary Langerhans cell histiocytosis, 1 (2.9%); other pulmonary fibrosis, 1 (2.9%). IPF, idiopathic pulmonary fibrosis; 
Cr, serum creatinine; NT-proBNP, n-terminal pro-brain natriuretic peptide; Coronary disease, need a medical treatment in preoperative 
coronary angiography; DM, diabetes mellitus; 6MWT, 6 minute walk test; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; 
DLCO, diffusion capacity for carbon monoxide; pre-op, preoperative; MV, mechanical ventilation; ECMO, extracorporeal membrane 
oxygenation; EF, ejection fraction; RWMA, regional wall motion abnormality; RAP, right arterial pressure; RVSP, right ventricular systolic 
pressure; E/E', ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E'); mPAP, mean pulmonary arterial 
pressure; RVP, right ventricular pressure; PCWP, pulmonary capillary wedge pressure; CO, cardiac output; CI, cardiac index; SD, standard 
deviation; IQR, interquartile range.
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Figure 1 Kaplan-Meier survival curve for 1-year mortality after 
lung transplantation, according to pulmonary hypertension status. 
PAP, pulmonary arterial pressure.
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Table 2 Results of univariate analysis of prognostic indicators for 
1-year mortality after lung transplantation
Variables HR (95% CI) P value
Age, years 1.085 (1.030–1.143) 0.002
Male gender, n (%) 0.416 (0.146–1.181) 0.099
Body mass index, kg/m2 1.249 (1.113–1.401) <0.001
Smoking, pack years 1.018 (0.985–1.052) 0.292
Underlying disease 0.123
IPF Reference range
Non-IPF* 0.467 (0.177–1.229)
Double LTX 2.913 (0.663–12.794) 0.157
Coronary disease 0.481 (0.159–1.368) 0.170
DM 1.444 (0.470–4.439) 0.521
6MWT, M 0.999 (0.995–1.004) 0.766
Echocardiography data
EF, % 1.019 (0.963–1.079) 0.514
RWMA, N (%) 0.801 (0.106–6.047) 0.851
RAP, mmHg 1.044 (0.943–1.156) 0.409
RVSP, mmHg 1.005 (0.984–1.027) 0.615
E/E' ratio 1.116 (0.944–1.320) 0.200
Hemodynamic data
mPAP ≥25, mmHg 4.444 (1.015–19.454) 0.048
RAP, mmHg 1.086 (1.021–1.155) 0.008
RVP, mmHg 1.008 (0.989–1.027) 0.407
PCWP, mmHg 1.035 (0.985–1.088) 0.177
CO, L/min 1.278 (0.717–2.277) 0.405
CI, L/min/m2 0.659 (0.240–1.808) 0.659
Pre-op MV 2.491 (0.88–7.686) 0.112
Pre-op ECMO 1.923 (0.254–14.557) 0.527
Donor
Age, years 0.983 (0.944–1.025) 0.425
Male gender 0.612 (0.197–1.898) 0.395
Body mass index, kg/m2 0.948 (0.794–1.131) 0.551
Table 2 (continued)
Table 2 (continued)
Variables HR (95% CI) P value
Smoking, pack years 0.933 (0.825–1.054) 0.265
Ischemic time, min 1.004 (0.997–1.012) 0.216
Size mismatch 1.972 (0.727–5.347) 0.182 
* ,  t h e  d i s t r i b u t i o n  o f  u n d e r l y i n g  l u n g  d i s e a s e s : 
lymphangioleiomyomatosis, 8 (28.6%); connective tissue 
disease, 6 (21.4%); bronchiectasis, 5 (17.6); bronchiolitis 
obliterans after stem cell transplantation, 4 (14.3%); diffuse 
panbronchiolitis, 2 (7.1); chronic obstructive pulmonary disease, 
1 (3.6%); pulmonary Langerhans cell histiocytosis, 1 (3.6%); 
other pulmonary fibrosis, 1 (3.6%). HR, hazard ratio; CI, 
confidence interval; mPAP, mean pulmonary arterial pressure; 
IPF, idiopathic pulmonary fibrosis; Coronary disease, need 
a medical treatment in preoperative coronary angiography; 
DM, diabetes mellitus; 6MWT, 6 minute walk test; EF, ejection 
fraction; RWMA, regional wall motion abnormality; RAP, right 
arterial pressure; RVSP, right ventricular systolic pressure; E/E′, 
ratio of mitral peak velocity of early filling (E) to early diastolic 
mitral annular velocity (E'); RVP, right ventricular pressure; 
PCWP, pulmonary capillary wedge pressure; CO, cardiac output; 
pre-op, preoperative; MV, mechanical ventilation; ECMO, 
extracorporeal membrane oxygenation; PGD, primary graft 
dysfunction. 
Table 3 Results of multivariate analysis of prognostic indicators for 
1-year mortality after lung transplantation
Variables HR (95% CI) P value
Age, years 1.067 (1.006–1.132) 0.030
Male gender 1.007 (0.244–4.157) 0.992
BMI, kg/m2 1.146 (1.003–1.309) 0.045
IPF vs. non-IPF 0.822 (0.190–3.566) 0.794
RAP, mmHg 1.028 (0.949–1.114) 0.492
mPAP ≥25, mmHg 4.832 (1.080–21.608) 0.039
HR, hazard ratio; CI, confidence interval; BMI, body mass index; 
IPF, idiopathic pulmonary fibrosis; RAP, right arterial pressure; 
mPAP, mean pulmonary arterial pressure.
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prognosis for 1-year survival post-LTX. 
Several studies and guidelines have defined PH as mPAP 
≥25 mmHg in patients with or without underlying diseases; 
in addition, RHC has been utilized as the “gold standard” 
for PH diagnosis (9,17,20). In the past, chest X-ray imaging 
and echocardiography were used to determine the presence 
and severity of PH (17). However, given its relatively 
high accuracy in the evaluation of PH status among lung 
transplant recipients, RHC is increasingly used in pre- 
and postoperative evaluation of PH. Although RHC is the 
most accurate method to diagnose PH, it is an invasive 
procedure. Therefore, echocardiography is preferred as the 
initial screening modality for diagnosis of PH. A few studies 
have used echocardiography to investigate mortality among 
lung transplant recipients with poor RV function (15,16,21). 
However, this diagnostic technology requires estimates 
of tricuspid regurgitation jet velocity and is associated with 
underestimation of pressures in patients with high PAP, as 
well as overestimation of PAP in patients without significant 
elevation (22,23). In the present study, the presence of 
PH was found in 68% of patients by RHC, whereas it 
was found in 77% of patients by use of echocardiography 
[defined as a pulmonary artery systolic pressure (PASP) 
of >35 mmHg]. Unfortunately, there was no correlation 
between echocardiography and survival (HR 1.005; 95% 
CI, 0.984–1.027; P=0.615). There was a positive correlation 
was observed between PASP estimated by echocardiography 
and measured by RHC (r=0.584, P<0.001). Although 
there is a good correlation in baseline PASP between 
echocardiography and RHC, echocardiographic PH 
measurements alone are not sufficient to monitor changes 
in PASP or progression of PH, as described in previous 
studies (24). Although it may serve as a good screening tool, 
echocardiographic PH measurement alone is not sufficient 
to predict mortality or postoperative outcome. Further 
large prospective cohort studies are required regarding the 
diagnosis of PH by echocardiography. 
In contrast to the present findings, Whitson et al. 
reported a lack of strong evidence for a relationship 
between preoperative PH and postoperative mortality (17). 
Furthermore, several studies have been unable to identify 
a statistically significant difference in survival between 
patients with PH and patients without PH (25,26). Because 
of these inconsistent results, the impact of preoperative PH 
on postoperative mortality is still controversial. However, 
most previous studies, including a large prospective cohort 
study, have reported high mortality or poor outcomes 
among lung transplant recipients with PH-associated lung 
disease (7,10-13,17,19,27-30). In addition, the variation in 
the impact of PH on post-transplantation mortality might 
be attributable to the heterogeneity of end-stage lung 
diseases among the present study population. In a recent 
publication, Gries et al. also reported differences in patient 
survival related to the underlying lung disease (30). 
A growing body of evidence suggests that age at 
operation, sex, BMI, preoperative albumin level, kidney 
Table 4 Postoperative complications within 3 months in lung transplant recipients 
Variables Patient without PH (n=16) Patient with PH (n=34) Total (n=50) P value
Pneumonia, n (%) 12 (75.0) 28 (82.4) 40 (80.0) 0.960
Sepsis, n (%) 3 (18.8) 15 (44.1) 18 (36.0) 0.081
AKI, n (%) 6 (37.5) 17 (50.0) 23 (46.0) 0.307
RRT, n (%) 2 (12.5) 13 (38.2) 15 (30.0) 0.113
Post-op bleeding, n (%) 2 (12.5) 6 (17.6) 8 (16.0) 0.960
Acute rejection, n (%) 0 (0.0) 4 (11.8) 4 (8.0) 0.383
Total HOD, days 41.4 (8.0–97.0) 59.5(23.0–159.0) 48.9 (25.3–74.3) 0.139
ICU stay after operation, days 7.0 (6.0–22.5) 8.5 (7.0–29.0) 8.0 (6.0–26.0) 0.535
Post-op MV, days 4.0 (3.0–19.0) 8.0 (4.0–19.0) 8.0 (4.0–19.0) 0.549
PGD grade 3, n (%) 1 (6.3) 7 (20.6) 8 (16.0) 0.197
Values are expressed as mean (SD) or median (IQR). SD, standard deviation; IQR, interquartile range; PH, pulmonary hypertension; AKI, 
acute kidney injury; RRT, renal replacement therapy; post-op, post-operative; HOD, day of hospital stay; ICU, intensive care unit; MV, 
mechanical ventilation; PGD, primary graft dysfunction.
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function, ischemic time, and size mismatch are significant 
prognostic factors for survival after LTX (7,21,30-32). The 
present findings differ from those of some previous reports 
regarding survival after LTX. In this study, significant 
prognostic factors for post-LTX survival were limited 
to age, sex, BMI, and PH (mPAP ≥25 mmHg). Upon 
multivariate analysis—performed to exclude the effect of 
non-PH factors, including underlying disease (IPF or non-
IPF), on survival—we found that the severity of PH, as 
defined by mPAP, was a prognostic factor for 1-year survival 
in lung transplant recipients. 
Unfortunately, most studies that have evaluated the 
risk factors of post-LTX mortality were performed in 
North America and Europe. As the medical environment 
and causes of LTX in Korea are very different relative to 
the previous studies, these differences may also affect the 
prognoses of patients undergoing LTX. Furthermore, the 
mortality rate in patients awaiting LTX in Korea was higher 
than in other countries (33-35). This may be attributable 
to the lack of donated lungs and the low utilization rate 
of donated lungs from brain-dead patients, which are 
the major obstacles to LTX in Korea, relative to other 
countries (36). 
To our knowledge, this was the first study to evaluate 
the clinical significance of post-LTX PH in Asian patients. 
Our results clearly demonstrated a significant correlation 
between mPAP and 1-year survival after LTX. In addition, 
the rate and severity of postoperative complications, such 
as sepsis, multi-organ dysfunction, postoperative bleeding, 
postoperative gastrointestinal bleeding, and grade 3 primary 
graft dysfunction, were higher among patients with PH 
than among patients without PH. For these reasons, we 
believe that PH is a significant prognostic factor for post-
LTX survival. 
In chronic lung diseases associated with PH, RV 
function is strongly influenced by the afterload (i.e., the 
underlying lung disease status) (17). Additionally, PH 
also causes distortion of cardiac geometry; however, post-
LTX echocardiographic findings have demonstrated 
reverse remodeling of the distorted cardiac geometry (37). 
Thus, for a variety of reasons, severe pulmonary disease 
affects both the right and left ventricles and leads to 
PH (38), which is considered to be associated with increased 
mortality. There is an increasing effort to produce evidence 
supporting this claim in specific lung diseases, such as cystic 
fibrosis (26,39,40). Collectively, these findings suggest that 
the presence of PH before LTX might affect the prognosis 
in lung transplant recipients. Therefore, further studies, 
involving a large number of patients with various end-
stage lung diseases, are required to evaluate the prognostic 
implication of preoperative PH in the clinical outcome 
of LTX.
Limitations of the present study include its relatively 
small sample size and retrospective study design solely 
involving medical record review. In addition, there is no 
apparent difference in the prognosis between severe PH and 
mild to moderate PH; this requires additional investigation. 
Despite these limitations, the strength of this study is 
that this was the first study to evaluate the prognostic 
significance of preoperative PH in Asian patients; moreover, 
the data were derived from a single center cohort. 
Considering that differences in ethnicity influence the 
outcome in patients with end-stage lung disease, data from 
our study could provide useful information regarding the 
prognosis of Asian patients undergoing LTX. 
In conclusion, patients with PH exhibited higher 1-year 
mortality after LTX, relative to patients without PH. 
PH associated with lung disease has been shown to be a 
predictor of the severity of disease and mortality in patients 
awaiting LTX. Thus, the evaluation of PH by preoperative 
RHC might be essential in patients who are awaiting LTX. 
Larger prospective studies are required to verify the benefit 
of early transplantation in patients with PH, following 
evaluation by echocardiography and RHC. Furthermore, 
earlier transplantation should be considered before the 
occurrence of end-stage lung disease in patients with PH.
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